- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Eur J Gastroenterol Hepatol. 2012 Jan 23.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22273989
Age versus clinical virological characteristics in chronic hepatitis B
virus infection: a case series study in China. Wu DL, Xu GH, Lu SM, Ma BL,
Miao NZ, Liu XB, Feng JH, Liu N, Zeng QL, Hou WK, Pei L, Zhao Y.
SourceaDepartment of Genetics and Molecular Biology, School of Medicine
bKey Laboratory of Environment and Genes Related Diseases of Ministry of
Education cDepartment of Epidemiology and Health Statistics, School of
Public Health dDepartment of Infectious Diseases, First Affiliated Hospital
of Medical College, Xi'an Jiaotong University, Xi'an eDepartment of
Infectious Diseases, Affiliated Hospital of Yan'an University fMedical
College of Yan'an University, Yan'an, Shaanxi Province, China.
Abstract
OBJECTIVES: This study aimed to investigate the clinical virological
characteristics of hepatitis B virus (HBV) in chronic HBV infection
patients of different ages, especially in relapse patients and patients
with immune clearance. METHODS: The HBV clinical virological
characteristics of chronic HBV infection were investigated in 1572 Chinese
patients of different age groups (<20, 20-40, and >40 years old). RESULTS:
Of the patients in the below 20 age group, those with evidence of immune
tolerance accounted for 86.05% (P<0.001). Of the patients in the 20-40 age
group, those with immune clearance accounted for 36.36% (P<0.001). Of the
patients in the above 40 age group, there were markedly more reactivation
cases than in any other group (P<0.001). Our data indicated that a positive
correlation (r=0.480, P<0.001) existed between HBV DNA contents (on a
log10 scale) and the alanine aminotransferase (ALT) level of the total
cases with reactivation. Of the 300 cases with immune clearance being
followed up 10-50 months after enrollment, 181 cases achieved spontaneous
hepatitis B e antigen (HBeAg) seroconversion (HBeAg to anti-HBe), and the
younger the patient, the shorter the time to seroconversion (P<0.05).
CONCLUSION: Generally, there were significantly different HBV clinical
virological characteristics in patients with chronic HBV infection of
different ages. Different features were observed in relapse patients and
patients with immune clearance at different ages, and these two types of
patients needed antiretroviral therapy. Our study suggests that revisions
of the timing and elevated alanine aminotransferase standards for chronic
hepatitis B antiretroviral therapy in Chinese relapse patients and patients
with immune clearance in different age groups are warranted.
|
|